Literature DB >> 29778255

Elimination of Hepatitis C Virus in Australia: Laying the Foundation.

Gregory J Dore1, Behzad Hajarizadeh2.   

Abstract

Australia is on-track to achieve World Health Organization hepatitis C virus (HCV) elimination targets. An active HCV screening program led to 82% of HCV-infected population being diagnosed. An unrestricted direct-acting antiviral (DAA) program, launched in March 2016 resulted in an estimated 58,500 individuals (26% of total HCV-infected population, including 70% of those with cirrhosis) initiating treatment through 2017. Treatment uptake was high among sub-populations at greater HCV transmission risk with 22% of people injecting drugs and >60% of those with HIV/HCV coinfection initiating DAA treatment in 2016. A monitoring and evaluation program will inform strategies required to achieve HCV elimination targets. Crown
Copyright © 2018. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Australia; Direct acting antivirals, DAA, public health; Elimination; Hepatitis C, HCV; People who inject drugs

Mesh:

Substances:

Year:  2018        PMID: 29778255     DOI: 10.1016/j.idc.2018.02.006

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  11 in total

1.  Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.

Authors:  Heather Valerio; Maryam Alavi; David Silk; Carla Treloar; Marianne Martinello; Andrew Milat; Adrian Dunlop; Jo Holden; Charles Henderson; Janaki Amin; Phillip Read; Philippa Marks; Louisa Degenhardt; Jeremy Hayllar; David Reid; Carla Gorton; Thao Lam; Gregory J Dore; Jason Grebely
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

Review 2.  Hepatitis C elimination: a Public Health Perspective.

Authors:  Radha K Dhiman; Gagandeep S Grover; Madhumita Premkumar
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

3.  The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges.

Authors:  M Behzadifar; S Azari; H A Gorji; M Martini; N L Bragazzi
Journal:  J Prev Med Hyg       Date:  2020-04-02

4.  Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care.

Authors:  David Brain; Jonathan Mitchell; James O'Beirne
Journal:  PLoS One       Date:  2020-06-17       Impact factor: 3.240

5.  Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019.

Authors:  Anna Lee Wilkinson; Alisa Pedrana; Michael W Traeger; Jason Asselin; Carol El-Hayek; Long Nguyen; Victoria Polkinghorne; Joseph S Doyle; Alexander J Thompson; Jessica Howell; Nick Scott; Wayne Dimech; Rebecca Guy; Margaret Hellard; Mark Stoové
Journal:  Epidemiol Infect       Date:  2021-12-06       Impact factor: 2.451

6.  Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project.

Authors:  Julia A Silano; Carla Treloar; Kyle Leadbeatter; Sandy Davidson; Justine Doidge
Journal:  Harm Reduct J       Date:  2022-04-21

7.  Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.

Authors:  Samira Hosseini-Hooshyar; Maryam Alavi; Marianne Martinello; Heather Valerio; Shane Tillakeratne; Gail V Matthews; Gregory J Dore
Journal:  J Viral Hepat       Date:  2022-02-25       Impact factor: 3.517

Review 8.  Current impact of viral hepatitis on liver cancer development: The challenge remains.

Authors:  Ângelo Zambam de Mattos; Jose D Debes; Andre Boonstra; Ju-Dong Yang; Domingo C Balderramo; Giovana D P Sartori; Angelo Alves de Mattos
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

9.  Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.

Authors:  Jisoo A Kwon; Gregory J Dore; Behzad Hajarizadeh; Maryam Alavi; Heather Valerio; Jason Grebely; Rebecca Guy; Richard T Gray
Journal:  PLoS One       Date:  2021-09-16       Impact factor: 3.240

10.  High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.

Authors:  Jasmine Yee; Joanne M Carson; Behzad Hajarizadeh; Joshua Hanson; James O'Beirne; David Iser; Phillip Read; Anne Balcomb; Joseph S Doyle; Jane Davies; Marianne Martinello; Philiipa Marks; Gregory J Dore; Gail V Matthews
Journal:  Hepatol Commun       Date:  2021-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.